TokenPost·

CG Oncology Shares Rise About 9% After Phase 3 Bladder Cancer Data

Your call?

The data involved cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.

Share

More news